Format

Send to

Choose Destination
See comment in PubMed Commons below
Surg Today. 2010 Oct;40(10):936-42. doi: 10.1007/s00595-009-4171-x. Epub 2010 Sep 25.

Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors.

Author information

1
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, PR China.

Abstract

PURPOSE:

To evaluate the effectiveness of resecting liver metastases of gastrointestinal stromal tumors (GISTs), when performed in conjunction with imatinib treatment.

METHODS:

Forty-one patients with pathologically diagnosed GIST and liver metastases were randomly assigned to an operation group (neoadjuvant therapy + resection + adjuvant therapy with imatinib) or a nonoperation group (imatinib alone). Patients were monitored for up to 36 months, and survival was analyzed.

RESULTS:

We monitored 39 patients throughout the 36-month follow-up period, recording 1- and 3-year survival rates of 100% and 89.5% in the operation group and 85% and 60% in the nonoperation group, respectively. There was a significant difference in overall survival between the operation and nonoperation groups (P = 0.03). Furthermore, resection improved the survival of patients who responded poorly to 6 months of preoperative imatinib treatment, compared with that of their counterparts in the nonoperation group (P = 0.04).

CONCLUSION:

These findings suggest that surgical intervention in combination with imatinib treatment is more effective than imatinib alone against GIST liver metastases, with minimal complications and side effects.

PMID:
20872196
DOI:
10.1007/s00595-009-4171-x
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center